Format

Send to

Choose Destination
Inflamm Res. 2007 Jun;56(6):240-5.

Effect of rectal administration of rebamipide on dextran sulfate sodium-induced colitis: role of hepatocyte growth factor.

Author information

1
Division of Molecular and Genetic Medicine, Department of Genetic Medicine and Regenerative Therapeutics, Graduate School of Medicine, Tottori University, Yonago 683-8504, Japan.

Abstract

OBJECTIVE AND DESIGN:

Since rebamipide is effective for the treatment of ulcerative colitis (UC), we examined the involvement of hepatocyte growth factor (HGF) in the action of rebamipide.

MATERIALS:

Fifty-five and forty female Balb/c mice, respectively, were used in Exp. 1 and 2.

TREATMENT:

50 mg/kg/day rebamipide (Exp. 1) and 1 x 10(7) pfu pAxCAHGF (the CAG promoter-driving HGF gene in adenovirus vector) (Exp. 2) were intrarectally introduced after induction of colitis by 4 % dextran sulfate sodium (DSS).

METHODS:

Therapeutic effects were assessed by cell proliferation and apoptosis.

RESULTS:

Rebamipide caused proliferation of epithelial cells at 10 days after treatment, and decreased apoptosis at 10, 14 and 21 days, compared with controls. Expression of HGF was greatly increased in rebamipide-treated mice. pAxCAHGF caused cell proliferation and apoptosis, which showed the same pattern as with rebamipide treatment.

CONCLUSIONS:

Rectal administration of rebamipide is effective for DSS-induced colitis in association with induction of HGF.

PMID:
17607548
DOI:
10.1007/s00011-007-6100-z
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center